LIVE

XENE

Xenon Pharmaceuticals Inc.

XENE

NASDAQ·Healthcare·Biotechnology·Mkt cap $4.8B

$60.33

▲ +0.05%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$30.00 - $63.95

P/E

-12.84

Fwd P/E

-13.08

Beta

0.63

Div Yield

0.00%

Avg Vol

1.3M

Shares Out

78.9M

Mkt Cap

$4.8B

Price action

Price chart

Up 80.7% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

5 reasons

  • Proprietary ion channel modulation platform with deep expertise in neurological targets
  • Advanced clinical pipeline with multiple Phase II/III assets reducing development risk
  • Strategic partnerships with established biotech firms (Neurocrine, Flexion) providing validation and resources
  • Focus on rare genetic neurological disorders with high unmet medical needs and potential for premium pricing
  • Experienced management team with track record in neurological drug development
▼

Bear Case

1 risk

  • Low volatility (beta 0.6).

Growth

Revenue decline expected

XEN496 Phase III trial progression for KCNQ2-related epilepsy with potential FDA approval pathway

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Strong

+6.1% over 3m

Quality

Loss-making

Solid business

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: May 11, 2026

“
Q2 26 RECAP

MAY 7, 2026

Reported EPS of -$1.17 vs -$1.17 consensus (0.0% surprise).

EPS beat 0.0%

EPS surprise · last 4Q

1 of 1 beats

Q2 26

0.0%

Next: May 11, 2026

Revenue trend · last 8Q

—

—

—

—

—

—

—

-100%

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$0

$0

$0

$7.5M

$0

$0

$0

$0

Margins · last 8Q

Gross

—

Profit

—

View full earnings history →

Wall Street consensus

8 analysts · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

8

100%

Hold

0%

Sell

0%

Median Price Target

$73.50

▲ +21.8% vs $60.33

Low $69.00
Median $73.50
High $78.00

Latest: JP Morgan · May 27, 2026

2 analysts covering

View full analyst page →

vs Industry

How XENE stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.